Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6427-6433

  Van Bergen, Jeroen ^a   Camps, Marcel ^a   Offringa, Rienk ^a   Melief, Cornelis J M ^a   Ossendorp, Ferry ^a   Koning, Frits ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN CLIP; SYNTHETIC PEPTIDE; T LYMPHOCYTE ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; HELPER CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RETROVIRIDAE PROTEINS, ONCOGENIC; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFECTION; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 0033722487     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. The role of CD4+ T cell responses in antitumor immunity
2. The central role of CD4+ T cells in the anti-tumor immune response
3. CD4 T cells and their role in antitumor immune responses
4. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
5. Specific T helper cell requirement for optimal induction of CTLs against MHC class II negative tumors
6. Immunization with a single T helper epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development
7. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP
8. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I binding motif, explains MuLV-type specificity of MCF-directed CTL
9. MHC class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas
10. Cloning of the MCF 1233 murine leukemia virus and identification of sequences involved in viral tropism, oncogenicity and T cell epitope formation
11. Host resistance directed selectively against H-2 deficient lymphoma variants
12. LacZ inducible, antigen/MHC-specific T cell hybrids
13. Get into the groove! Targeting antigens to MHC class II
14. Eradication of El-induced tumors by Ela-specific CTL
15. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site
16. Automated multiple peptide synthesis with BOP activation
17. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells
18. Identification of a gag-encoded CTL epitope from FBL-3 leukemia shared by Friend, Moloney and Rauscher murine leukemia-induced tumors
19. Fibroblasts as efficient antigen-presenting cells in lymphoid organs
20. Signal and membrane anchor functions overlap in the type II membrane protein I γ CAT
21. Visualization of peptide-specific T cell immunity mid peripheral tolerance induction in vivo
22. T cell priming versus T cell tolerance induced by synthetic peptides
23. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
24. Immune surveillance against a soluble tumor fails because of immunological ignorance
25. Natural adjuvants: Endogenous activators of dendritic cells
26. Antigen-specific immunotherapy for murine lung metastatic tumors expressing HPVI6 E7 oncoprotein
27. Treatment of estabhshed tumors with a novel vaccine that enhances MHC class II presentation of tumor antigen
28. Engineering an intracellular pathway for MHC class II presentation of antigens
29. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
30. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
31. Dendritic cells retrovirally transduced with a model antigen are therapeutically effective against established pulmonary metastases
32. Dominance and crypticity of T cell antigenic determinants